Randomized phase III study of irinotecan/cisplatin (IP) versus etoposide/cisplatin (EP) for completely resected high-grade neuroendocrine carcinoma (HGNEC) of the lung: JCOG1205/1206.

Hirotsugu Kenmotsu,Seiji Niho,Masahiro Tsuboi,Masashi Wakabayashi,Genichiro Ishii,Kazuo Nakagawa,Haruko Daga,Hiroshi Tanaka,Haruhiro Saito,Keiju Aokage,Toshiaki Takahashi,Toshi Menju,Takashi Kasai,Ichiro Yoshino,Koichi Minato,Morihito Okada,Hiroshi Katayama,Hisao Asamura,Yuichiro Ohe,Shun-ichi Watanabe

Randomized phase III study of irinotecan/cisplatin (IP) versus etoposide/cisplatin (EP) for completely resected high-grade neuroendocrine carcinoma (HGNEC) of the lung: JCOG1205/1206.

2020

9006Background: In the WHO classification, small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) are considered as high-grade neuroendocrine carcinoma (HGNEC) of the lung. A...

Keywords:

Cisplatin
neuroendocrine carcinoma
Irinotecan
Pathology
Lung
Etoposide
Medicine
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations